See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic that is used to treat various bacterial infections. It is a glycylcycline antibiotic, which is a class of drugs that is derived from tetracyclines. Tigecycline is effective against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria.

According to the drug's prescribing information, tigecycline is indicated for the treatment of complicated skin and skin structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CABP) caused by susceptible bacteria.

The bacteria that tigecycline is active against include:

* Gram-positive bacteria: Enterococcus faecium (vancomycin-resistant), Staphylococcus aureus (methicillin-susceptible and -resistant), Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, and Streptococcus pneumoniae (penicillin-susceptible isolates only).
* Gram-negative bacteria: Acinetobacter baumannii, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
* Anaerobic bacteria: Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Peptostreptococcus anaerobius.

It is important to note that the effectiveness of tigecycline against these bacteria may vary depending on the specific strain and the location of the infection. Therefore, it is crucial to perform susceptibility testing to guide therapy.

According to DrugPatentWatch.com, tigecycline is marketed under the brand name Tygacil and is manufactured by Pfizer. The drug was first approved by the FDA in 2005, and its patent expired in 2015.

In summary, tigecycline is a broad-spectrum antibiotic that is used to treat various bacterial infections, including cSSSI, cIAI, and CABP. It is active against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria. The drug's patent expired in 2015, and it is marketed under the brand name Tygacil.

Sources:

1. Tygacil (tigecycline) prescribing information. Pfizer. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s013s014lbl.pdf>
2. DrugPatentWatch.com. Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>